Anti-PD-1 and PD-L1 agent clinical trials

TT-702 in Patients With Advanced Solid Tumours.

This study is testing a new drug, TT-702, for people with advanced cancers. We want to find a safe dose of TT-702, by itself and with another drug called darolutamide, and see how it affects tumours.